Clinical Trial Update: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) [Phase 2]

View source ↗

Summary

This Phase 2 trial update covers belzutifan (MK-6482) for advanced pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, von Hippel-Lindau disease–a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Hif-2α-mutated Cancers
• Pancreatic Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma
• Von Hippel-lindau Disease

Drugs mentioned

• Belzutifan (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor | Phase 2 | Status: RECRUITING